Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
SEC Accession No. 0000921895-25-003090
Filing Date
2025-11-14
Accepted
2025-11-14 16:00:31
Documents
1

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13G/A  
1 primary_doc.xml SCHEDULE 13G/A 23872
  Complete submission text file 0000921895-25-003090.txt   25765
Mailing Address 44 MONTGOMERY STREET 40TH FL SAN FRANCISCO CA 94104
Business Address 44 MONTGOMERY STREET 40TH FL SAN FRANCISCO CA 94104 3125066500
BIOTECHNOLOGY VALUE FUND L P (Filed by) CIK: 0000918923 (see all company filings)

EIN.: 363924731 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13G/A
SIC: 6282 Investment Advice
(CF Office: 02 Finance)

Mailing Address 1500 LIBERTY RIDGE DRIVE SUITE 321 WAYNE PA 19087
Business Address 1500 LIBERTY RIDGE DRIVE SUITE 321 WAYNE PA 19087 410-522-8707
Avalo Therapeutics, Inc. (Subject) CIK: 0001534120 (see all company filings)

EIN.: 450705648 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13G/A | Act: 34 | File No.: 005-89290 | Film No.: 251485473
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)